tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

BioAge Labs downgraded to Underweight from Overweight at Morgan Stanley

Morgan Stanley downgraded BioAge Labs (BIOA) to Underweight from Overweight with a price target of $5, down from $40. The company discontinued its STRIDES trial following cases of liver transaminitis, which removes the key clinical catalyst for next year, the analyst tells investors in a research note. The firm downgraded shares on a relative basis as it sees better opportunities elsewhere for 2025.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1